Literature DB >> 10356309

Identification and characterization of the molecular lesion causing mucopolysaccharidosis type I in cats.

X He1, C M Li, C M Simonaro, Q Wan, M E Haskins, R J Desnick, E H Schuchman.   

Abstract

Mucopolysaccharidosis Type I (MPS I) is the lysosomal storage disease caused by the deficient activity of alpha-L-iduronidase (IDUA). In man, MPS I can occur in severe, mild, or intermediate forms known as the Hurler, Scheie, or Hurler/Scheie syndromes, respectively. MPS I also has been described in cats, dogs, and mice. This manuscript reports the identification and characterization of the mutation causing MPS I in cats. To obtain wild-type feline IDUA cDNAs, two PCR-based strategies were used. PCR primers were constructed from a conserved region of the published human and dog sequences and used to amplify a 224-bp IDUA fragment from normal cat genomic DNA. This fragment was then used to screen a feline uterus cDNA library. PCR also was used to directly amplify IDUA fragments from the same cDNA library. Two overlapping feline IDUA cDNAs encoding 466 amino acid residues of the feline IDUA polypeptide ( approximately 85% of the mature protein based on comparison to the human, dog, and mouse sequences) were obtained by these strategies. To identify the mutation causing MPS I in cats, DNA sequencing was carried out on the corresponding IDUA region from several affected animals. A 3-bp deletion was found on both IDUA alleles in each of the MPS I animals, predicting the deletion of a single aspartate residue from the feline IDUA polypeptide. To confirm the authenticity of this mutation, heteroduplex, SSCP, and transient expression studies were carried out. Over 100 animals from the MPS I colony were screened for the presence of the mutation by heteroduplex and SSCP analyses-in all cases the presence of the 3-bp deletion was 100% concordant with the disease phenotype. For transient expression studies, the two partial, overlapping feline cDNAs were combined and joined in-frame to the 5' end of the canine IDUA cDNA. This wild-type, hybrid cDNA expressed IDUA activity up to sixfold over endogenous levels after transfection into COS-1 cells. A modified full-length IDUA cDNA containing the 3-bp deletion did not express IDUA activity in a transient expression system, providing proof that this lesion was the cause of feline MPS I. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10356309     DOI: 10.1006/mgme.1999.2860

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  19 in total

1.  Intrathecal gene therapy corrects CNS pathology in a feline model of mucopolysaccharidosis I.

Authors:  Christian Hinderer; Peter Bell; Brittney L Gurda; Qiang Wang; Jean-Pierre Louboutin; Yanqing Zhu; Jessica Bagel; Patricia O'Donnell; Tracey Sikora; Therese Ruane; Ping Wang; Mark E Haskins; James M Wilson
Journal:  Mol Ther       Date:  2014-07-16       Impact factor: 11.454

2.  Liver-directed gene therapy corrects cardiovascular lesions in feline mucopolysaccharidosis type I.

Authors:  Christian Hinderer; Peter Bell; Brittney L Gurda; Qiang Wang; Jean-Pierre Louboutin; Yanqing Zhu; Jessica Bagel; Patricia O'Donnell; Tracey Sikora; Therese Ruane; Ping Wang; Mark E Haskins; James M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-29       Impact factor: 11.205

Review 3.  Large animal models of neurological disorders for gene therapy.

Authors:  Christine Gagliardi; Bruce A Bunnell
Journal:  ILAR J       Date:  2009

Review 4.  Gene therapy for lysosomal storage diseases (LSDs) in large animal models.

Authors:  Mark Haskins
Journal:  ILAR J       Date:  2009

5.  Bone marrow transplantation for feline mucopolysaccharidosis I.

Authors:  N Matthew Ellinwood; Marie-Anne Colle; Margaret A Weil; Margret L Casal; Charles H Vite; Staci Wiemelt; Christopher W Hasson; Thomas M O'Malley; Xingxuan He; Ulana Prociuk; Lucie Verot; John R Melniczek; Anne Lannon; Gustavo D Aguirre; Van W Knox; Sydney M Evans; Marie T Vanier; Edward H Schuchman; Steven U Walkley; Mark E Haskins
Journal:  Mol Genet Metab       Date:  2007-05-07       Impact factor: 4.797

6.  Radiographic evaluation of bones and joints in mucopolysaccharidosis I and VII dogs after neonatal gene therapy.

Authors:  Ramin Sedaghat Herati; Van W Knox; Patricia O'Donnell; Marina D'Angelo; Mark E Haskins; Katherine P Ponder
Journal:  Mol Genet Metab       Date:  2008-08-15       Impact factor: 4.797

7.  Initial sequence and comparative analysis of the cat genome.

Authors:  Joan U Pontius; James C Mullikin; Douglas R Smith; Kerstin Lindblad-Toh; Sante Gnerre; Michele Clamp; Jean Chang; Robert Stephens; Beena Neelam; Natalia Volfovsky; Alejandro A Schäffer; Richa Agarwala; Kristina Narfström; William J Murphy; Urs Giger; Alfred L Roca; Agostinho Antunes; Marilyn Menotti-Raymond; Naoya Yuhki; Jill Pecon-Slattery; Warren E Johnson; Guillaume Bourque; Glenn Tesler; Stephen J O'Brien
Journal:  Genome Res       Date:  2007-11       Impact factor: 9.043

8.  Characterization of an MPS I-H knock-in mouse that carries a nonsense mutation analogous to the human IDUA-W402X mutation.

Authors:  Dan Wang; Charu Shukla; Xiaoli Liu; Trenton R Schoeb; Lorne A Clarke; David M Bedwell; Kim M Keeling
Journal:  Mol Genet Metab       Date:  2010-01       Impact factor: 4.797

Review 9.  Animal models for mucopolysaccharidosis disorders and their clinical relevance.

Authors:  Mark E Haskins
Journal:  Acta Paediatr       Date:  2007-04       Impact factor: 2.299

Review 10.  Pathogenesis and treatment of spine disease in the mucopolysaccharidoses.

Authors:  Sun H Peck; Margret L Casal; Neil R Malhotra; Can Ficicioglu; Lachlan J Smith
Journal:  Mol Genet Metab       Date:  2016-06-04       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.